Adocia jumps on Phase I/II diabetes data

Adocia S.A. (Euronext:ADOC) jumped EUR 2.38 (18%) to EUR 15.30 on Thursday after reporting preliminary data from a Phase I/II trial evaluating its BioChaperone insulin combo to treat Type I diabetes. In 20 diabetics, 0.8 IU/kg BioChaperone insulin combo had a 30% faster onset of action -- defined as the time to a 5% or greater reduction in glucose from baseline -- vs. 0.8 IU/kg Humalog Mix insulin lispro/insulin lispro protamine from Eli Lilly and Co. (NYSE:LLY).

BioChaperone insulin combo comprises a version of Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY) that uses Adocia's BioChaperone polymer technology in combination with Lilly's Humalog insulin lispro. Last year, Adocia and Lilly mutually terminated a December 2011 deal to develop and commercialize a version of Humalog with Adocia's BioChaperone technology. Adocia retained IP developed under the deal. ...